Bionexus Gene Lab regains Nasdaq compliance

BioNexus Gene Lab (BGLC) has received official notification from The Nasdaq Stock Market confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.In parallel with achieving Nasdaq compliance, BGLC has taken decisive steps to strengthen corporate governance, enhance internal controls, and position itself for strategic partnerships, capital raising, and M&A activity. This includes the appointment of new independent board members, the formation of a dedicated internal audit function, and the retention of U.S.-based investment banking support for long-term value creation initiatives.